Cyclodextrin Imatinib Inhalation Formulation for Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for imatinib, such as subcutaneous or oral administration, face challenges in achieving effective therapeutic concentrations in pulmonary conditions, and inhalable formulations suffer from adverse organoleptic properties and inefficient lung delivery.
Innovation Solution
A pharmaceutical composition comprising imatinib or its derivatives and cyclodextrin in an aqueous solution or suspension, designed for inhalation, which provides enhanced solubility and improved organoleptic properties, allowing for efficient delivery to the lungs with reduced adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If imatinib is administered via subcutaneous or oral delivery, then therapeutic effects can be achieved, but effective therapeutic concentrations in pulmonary conditions are difficult to achieve
Solution Approach 1:
Cyclodextrin is used as a solubility-enhancing agent to improve the dissolution and absorption of imatinib in the pulmonary system. The cyclodextrin forms inclusion complexes with imatinib, increasing its aqueous solubility and enabling effective pulmonary delivery while maintaining therapeutic concentrations in the lungs.
Solution Approach 2:
The patent modifies the physical and chemical parameters of imatinib by formulating it with cyclodextrin, changing its solubility characteristics. This parameter change enables the drug to achieve effective concentrations in pulmonary conditions through inhalation delivery, overcoming the limitations of subcutaneous or oral administration.
2Ease of operation
If inhalable formulations are used to improve pulmonary delivery, then direct lung targeting is achieved, but adverse organoleptic properties and inefficient lung delivery occur
Solution Approach 1:
Cyclodextrin serves as a mediator that improves the organoleptic properties of the inhalable imatinib formulation. It enhances solubility and stability, reduces irritation, and improves the overall acceptability of the inhalation formulation while maintaining efficient lung delivery.
Solution Approach 2:
The formulation with cyclodextrin changes the physical parameters of the inhalable solution, improving its organoleptic properties such as solubility, stability, and irritation profile. This enables efficient pulmonary delivery without the adverse effects associated with conventional inhalable formulations.
3Quantity of substance
If conventional delivery methods are used, then administration is simple, but pharmacokinetic profile does not achieve optimal therapeutic levels
Solution Approach 1:
Cyclodextrin acts as a solubility-enhancing intermediary that improves the pharmacokinetic profile of imatinib. It increases aqueous solubility, enhances bioavailability, and optimizes plasma concentration levels, achieving better therapeutic outcomes while maintaining a relatively simple formulation approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves a pharmacokinetic profile with high lung concentrations and therapeutic advantages, minimizing adverse reactions and improving patient compliance through faster, more effective drug delivery.
Implementation Method 1
a pharmaceutical composition comprises an aqueous solution or suspension that comprises imatinib or a derivative thereof and cyclodextrin
Data Source
AI summary
Pharmaceutical compositions comprising imatinib or a derivative thereof for treatment of a pulmonary disease via inhalation. Methods of treating a pulmonary disease include administering by inhalation an effective amount of imatinib or a derivative thereof to a patient in need thereof. In aspects, the pharmaceutical composition provided herein comprises an aqueous solution or suspension of imatinib or a derivative thereof that is formulated for inhalational administration.